Canine Melanoma Oral Treatment Vaccine

Excellent workup on this case. Oral malignant melanoma is always a top concern, and your diagnostic and staging plan is spot on. The rostral location is a favorable prognostic indicator for achieving local control.

Here is my assessment and plan:

Staging is Paramount: Absolutely complete the three-view thoracic radiographs, regional lymph node aspirate (mandibular), and abdominal ultrasound before any definitive surgical planning. The high mitotic index (MI > 3) and size (>2cm) place this dog at high risk for metastasis. The results of staging will determine if our goal is curative-intent or palliative.

Local Control: A rostral mandibulectomy is the treatment of choice for local disease control. This procedure can be curative from a local perspective if clean margins are achieved, and dogs typically have an excellent functional and cosmetic outcome. I'll defer to Dr. Okafor for the surgical specifics and margin recommendations.

Systemic Control: Given the high metastatic potential, adjuvant therapy is critical.

* Oncept Vaccine: Your proposed protocol is correct. This is our primary recommendation for controlling micrometastatic disease in patients with loco-regionally controlled (Stage I, II, or III) melanoma. It stimulates an immune response against tyrosinase-expressing melanoma cells.
* Chemotherapy: Carboplatin is another option, often used if the vaccine is declined or if overt metastatic disease is present. The data supporting the vaccine for micrometastatic disease is generally considered stronger.

Prognosis & Survival Times: This is where we must be direct with the client.

* No Treatment: Median survival time (MST) is poor, typically 60-90 days, with progression of the local tumor causing significant quality of life issues.
* Surgery Alone: MST improves to approximately 5-7 months, but over 80% of dogs will develop distant metastasis.
* Surgery + Oncept Vaccine: This combination offers the best prognosis for dogs with loco-regionally controlled disease. Published data suggests an MST >500 days (~16-18 months).

My recommendation is to proceed with full staging. If negative for distant metastasis, move forward with the rostral mandibulectomy followed by the Oncept vaccine protocol starting 10-14 days post-operatively. This plan provides the best chance for long-term, good-quality survival.

Dr. Okafor, please weigh in on the surgical approach for this 2.5cm rostral mandibular mass.

Colleague, this is a classic and challenging case. An MI of 8 confirms this is an aggressive tumor, and our plan needs to reflect that. The goal of surgery here is aggressive local control, which is the single most important factor we can influence for this patient's quality of life.

Your staging plan is appropriate. I would strongly recommend adding a contrast-enhanced CT of the head and neck. While radiographs give us a general idea, a CT is far superior for defining the extent of bone invasion and planning precise surgical margins. It also provides a much more sensitive assessment of the mandibular and retropharyngeal lymph nodes than palpation and FNA alone. Dr. Lin's read on that CT would allow me to plan the osteotomies with confidence.

Assuming staging is clear of gross metastasis, a rostral mandibulectomy is the correct surgical approach. For a 2.5 cm melanoma, I would plan for at least 2 cm of clean bone margins rostral and caudal to the mass, which is achievable in this location. The procedure is functionally and cosmetically well-tolerated. Owners should be prepared for some tongue lolling and drooling, but most dogs return to eating soft food within 24-48 hours and adapt remarkably well. The cosmetic change is present but not disfiguring for most owners.

My role is to achieve clean margins on the first attempt. However, even with complete local excision, the high metastatic rate is the life-limiting factor. Surgery alone is not enough for these aggressive tumors. I'll defer to Dr. Torres on the specifics of the Oncept vaccine protocol and expected survival times, as that is central to her domain of managing systemic disease. I'll await the full staging results from Dr. Lin before booking the OR.

Colleagues, a sound initial plan. From an imaging perspective, let's refine the staging protocol to maximize the diagnostic yield and guide the therapeutic plan effectively.

Oral melanoma is aggressive with a high metastatic potential. Our primary goals with imaging are to define the extent of local disease for surgical planning and to accurately detect regional and distant metastasis.

1. Local and Regional Disease Assessment:
For a rostral mandibulectomy, radiographs of the mandible are insufficient. I strongly recommend a contrast-enhanced CT scan of the head and neck. This is the gold standard for several reasons:
* It will precisely define the extent of bone invasion, which is critical for determining surgical margins.
* It provides superior evaluation of the mandibular and medial retropharyngeal lymph nodes, which are the primary drainage sites. Ultrasound of this region can be challenging. CT allows for assessment of size, shape, and contrast enhancement patterns, guiding FNA or excisional biopsy.

2. Distant Metastasis — Thorax:
Your plan for thoracic radiographs is appropriate for screening. However, it is imperative to obtain three views (right lateral, left lateral, and a ventrodorsal). A single lateral view can easily miss nodules in the dependent lung due to atelectasis.

Be aware of the limitations: radiographs will only detect pulmonary nodules larger than 7-9 mm. For a tumor with a high metastatic rate, a thoracic CT scan is far more sensitive, capable of detecting nodules as small as 1-2 mm. If the owner is amenable, a single anesthesia event for a head/neck and thoracic CT provides the most accurate staging data.

3. Distant Metastasis — Abdomen:
A complete abdominal ultrasound is the correct modality here. We will systematically evaluate all visceral organs, particularly the liver and spleen, for metastatic nodules. We will also assess the intra-abdominal lymph nodes. Any abnormalities should be sampled via FNA under ultrasound guidance.

In summary, the ideal imaging workup is a comprehensive CT scan (head/neck and thorax) and an abdominal ultrasound. If CT is not feasible, three-view thoracic radiographs are the minimum standard, but you and the owner must accept their lower sensitivity for detecting early metastatic disease.